Neurocrine Biosciences (NBIX) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 293.4% versus a gain of 1.6%. Over five years, RVMD leads with a +598.0% price change compared with +35.1% for NBIX. Revolution Medicines is the larger company by market cap ($40.32 billion vs $14.36 billion), about 2.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | RVMD |
|---|---|---|
| Share price | $141.25 | $188.12 |
| Market cap | $14.36B | $40.32B |
| 1-day change | -1.55% | -6.35% |
| YTD return | -0.41% | +136.18% |
| 1-year return | +1.56% | +293.39% |
| 5-year return | +35.12% | +598.03% |
| P/E ratio (TTM) | 20.71 | — |
| Forward P/E | 11.89 | — |
| EPS (TTM) | $6.82 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.86B | $0 |
| Revenue growth (YoY) | +21.45% | — |
| Net income (latest FY) | $478.60M | $-1.13B |
| Gross margin | 98.18% | — |
| Operating margin | 21.64% | — |
| Net margin | 16.73% | — |
| 52-week high | $186.12 | $224.31 |
| 52-week low | $122.14 | $47.28 |
| Distance from 52-week high | -24.11% | -16.13% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +46.75% | +37.59% |
| Average volume | 1.30M | 1.93M |
| Shares outstanding | 101.65M | 214.34M |
| Employees | 2,500 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revolution Medicines is about 2.8 times larger than Neurocrine Biosciences by market value ($40.32B vs $14.36B).
- RVMD has outperformed NBIX by 291.8 percentage points over the past year.
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
NBIX vs RVMD FAQ
Which is bigger, Neurocrine Biosciences or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.32B compared with $14.36B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, NBIX or RVMD?
RVMD returned +293.39% over the past 12 months, compared with +1.56% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Are Neurocrine Biosciences and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.